SG11201607075TA - Compositions and methods for the reduction or prevention of hepatic steatosis - Google Patents

Compositions and methods for the reduction or prevention of hepatic steatosis

Info

Publication number
SG11201607075TA
SG11201607075TA SG11201607075TA SG11201607075TA SG11201607075TA SG 11201607075T A SG11201607075T A SG 11201607075TA SG 11201607075T A SG11201607075T A SG 11201607075TA SG 11201607075T A SG11201607075T A SG 11201607075TA SG 11201607075T A SG11201607075T A SG 11201607075TA
Authority
SG
Singapore
Prior art keywords
prevention
compositions
reduction
methods
hepatic steatosis
Prior art date
Application number
SG11201607075TA
Inventor
Michael Zemel
Antje Bruckbauer
Original Assignee
Nusirt Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201461945412P priority Critical
Application filed by Nusirt Sciences Inc filed Critical Nusirt Sciences Inc
Priority to PCT/US2015/018182 priority patent/WO2015131152A1/en
Publication of SG11201607075TA publication Critical patent/SG11201607075TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
SG11201607075TA 2014-02-27 2015-02-27 Compositions and methods for the reduction or prevention of hepatic steatosis SG11201607075TA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201461945412P true 2014-02-27 2014-02-27
PCT/US2015/018182 WO2015131152A1 (en) 2014-02-27 2015-02-27 Compositions and methods for the reduction or prevention of hepatic steatosis

Publications (1)

Publication Number Publication Date
SG11201607075TA true SG11201607075TA (en) 2016-09-29

Family

ID=54009689

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607075TA SG11201607075TA (en) 2014-02-27 2015-02-27 Compositions and methods for the reduction or prevention of hepatic steatosis

Country Status (14)

Country Link
US (3) US9724319B2 (en)
EP (1) EP3110507A4 (en)
JP (1) JP2017506651A (en)
KR (1) KR20160119863A (en)
CN (1) CN106456997B (en)
AU (1) AU2015222754A1 (en)
CA (1) CA2939833A1 (en)
IL (1) IL247263D0 (en)
MX (1) MX2016011063A (en)
PH (1) PH12016501668A1 (en)
RU (1) RU2016138136A3 (en)
SG (1) SG11201607075TA (en)
WO (1) WO2015131152A1 (en)
ZA (1) ZA201605795B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6158801B2 (en) 2011-07-15 2017-07-05 ニューサート サイエンシーズ, インコーポレイテッド Compositions and methods for modulating the metabolic pathway
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
CN108295058A (en) 2012-11-13 2018-07-20 纽斯尔特科学公司 Compositions and methods for increasing energy metabolism
AU2014236687A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
RU2016138136A3 (en) 2014-02-27 2018-09-26
CN105380949A (en) * 2014-09-02 2016-03-09 健脂生物科技股份有限公司 Composition for curing high-fat diet-induced accumulation of fat in the livers
US20170312286A1 (en) * 2016-05-02 2017-11-02 Jansfat Biotechnology Co., Ltd. Compositions and methods for lipid metabolism disorder
WO2018118941A1 (en) 2016-12-19 2018-06-28 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936527A (en) 1969-12-19 1976-02-03 Damon Corporation Treatment of pets
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
NL7804375A (en) 1977-05-16 1978-11-20 Ralston Purina Co Food for animals.
DK150008C (en) 1981-11-20 1987-05-25 Benzon As Alfred Process for the preparation of a pharmaceutical orally multiple-units
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (en) 1992-05-12 2001-10-15 沖電気工業株式会社 The method of manufacturing a semiconductor device
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
LU88369A1 (en) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch amino acids branched chain
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5776913A (en) 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
CA2242646C (en) 1996-01-09 2005-10-18 Takashi Abe Amino acid composition
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
JP2002513795A (en) 1998-05-04 2002-05-14 ヨハネス ケーゼル アンドレアス Monomers, Knoevenagel condensation products of oligomers and polymers
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DK0862863T4 (en) 1997-01-09 2008-12-01 Nestle Sa Cereal product containing probiotics
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (en) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti therapeutic nutritive composition for patients with diabetes mellitus
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6063414A (en) 1997-08-18 2000-05-16 Seal Rock Technologies Incorporated Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value
JP3611456B2 (en) 1997-09-30 2005-01-19 日研化学株式会社 Theophylline sustained-release tablets
US6387419B1 (en) 1998-06-02 2002-05-14 Biofiber-Damino A/S Piglet feeding method
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6403142B1 (en) 1998-12-11 2002-06-11 Ralston Purina Company Hypoallergenic pet food
CN1161101C (en) 1998-12-17 2004-08-11 阿尔扎有限公司 Conversion of liquid filled gelation capsules into controlled release systems by multiple coatings
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
EP1169322B8 (en) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
FR2790645B1 (en) 1999-03-12 2001-06-08 Arkopharma Laboratoires food additives and cosmetic treatment method is based on a grape extract rich in polyphenols
AU7596100A (en) 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
JP2003529347A (en) 2000-01-25 2003-10-07 ジュヴェノン インコーポレイテッド Nutritional supplements for elderly pet
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
US8398546B2 (en) 2000-06-16 2013-03-19 Bodymedia, Inc. System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
US6517877B2 (en) 2000-12-29 2003-02-11 Martin Francis Gannon Animal food product
KR20030088453A (en) 2001-03-09 2003-11-19 소시에떼 데 프로듀이 네슬레 소시에떼아노님 Composition improving age-related physiological deficits and increasing longevity
US6338862B1 (en) 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
WO2003042362A2 (en) 2001-11-09 2003-05-22 Dana-Farber Cancer Institute, Inc. PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
EP1505967B1 (en) 2002-05-17 2016-07-13 Duke University Method for treating obesity
AT376854T (en) 2002-06-26 2007-11-15 Alza Corp Minimally compliant volume-efficient piston for osmotic drug delivery systems
FR2841784B1 (en) 2002-07-08 2007-03-02 Composition derived basic 1,3-diphenylprop-2en-1-one derivatives, preparation and uses
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
AU2003291637A1 (en) 2002-10-09 2004-05-04 Bodymedia, Inc. Apparatus for detecting, receiving, deriving and displaying human physiological and contextual information
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
JP2004305201A (en) 2002-11-27 2004-11-04 Hayashibara Biochem Lab Inc Method for controlling formation of acrylamide and use of the same
CN1504424A (en) 2002-12-05 2004-06-16 上海金创投资管理有限公司 Drinking water containing leucine for baby
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
CA2518735C (en) 2003-03-13 2012-05-15 Vector Usa Inc. A film having a liquid absorbed therein
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
CN100415224C (en) 2003-03-18 2008-09-03 诺瓦提斯公司 Compositions comprising fatty acids and amino acids
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
US20050042362A1 (en) 2003-04-02 2005-02-24 Clark Harry M. Pet food composition and method
AT390142T (en) 2003-05-14 2008-04-15 Indus Biotech Pvt Ltd A synergistic composition for the treatment of diabetes mellitus
US20070203083A1 (en) 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
JP2005097273A (en) 2003-08-19 2005-04-14 Toyo Shinyaku:Kk Athletic ability-enhancing composition
EP1667579A4 (en) 2003-09-12 2008-06-11 Bodymedia Inc Method and apparatus for measuring heart related parameters
JP2007510427A (en) 2003-11-03 2007-04-26 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Coated pet food composition
EP1685133A1 (en) 2003-11-19 2006-08-02 DSM IP Assets B.V. Manufacture of vitamin b6
EP1685833A1 (en) 2003-11-21 2006-08-02 Ajinomoto Co., Inc. Remedy for diabetes
WO2005053422A2 (en) 2003-11-26 2005-06-16 Hill's Pet Nutrition, Inc. Method to reduce odor of excreta from companion animals
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007527418A (en) 2003-12-29 2007-09-27 ザ ジェネラル ホスピタル コーポレーション Composition for treating or preventing obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
JP2008503475A (en) 2004-06-17 2008-02-07 フォーレスト ラボラトリーズ, インコーポレイテッドForest Laboratories, Inc. Formulations release of memantine has been modified
WO2006001278A1 (en) 2004-06-28 2006-01-05 Kao Corporation Ampk activator
CA2577442A1 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
CA2588818A1 (en) 2004-11-29 2006-06-01 Toyo Shinyaku Co., Ltd. Athletic ability enhancing composition
US20060165824A1 (en) 2005-01-26 2006-07-27 The Procter & Gamble Company Compositions, kits, and methods for enhancing gastrointestinal health
DE602006004963D1 (en) 2005-02-11 2009-03-12 Argenta Discovery Ltd Combination of methyl xanthine compounds and steroids for the treatment of chronic airway diseases
US20060188611A1 (en) 2005-02-18 2006-08-24 Emine Unlu Edible pet chew
US20090163476A1 (en) 2005-03-03 2009-06-25 Sirtris Pharmaceuticals, Inc. N-Phenyl Benzamide Derivatives as Sirtuin Modulators
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2006120007A2 (en) 2005-05-13 2006-11-16 Nestec S.A. Production of glucosamine from plant species
WO2006138227A1 (en) 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2007019416A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US20070077310A1 (en) 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
JP5329229B2 (en) 2005-12-02 2013-10-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Method for modifying the quality and / or stool frequency feces
US8557869B2 (en) 2006-01-10 2013-10-15 Hill's Pet Nutrition, Inc. Compositions and methods for promoting fat loss
KR20080108487A (en) 2006-02-28 2008-12-15 트르스티스 오브 보스톤 유니버시티 Metabolic regulators and uses thereof
DE102006016903A1 (en) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg inhaler
US20090182036A1 (en) 2006-05-10 2009-07-16 Krammer-Lukas Stephanie J M Animal food composition comprising genistein and polyunsaturated fatty acids
JP2007306851A (en) 2006-05-18 2007-11-29 仁 ▲吉▼井 Salt composition and method for producing the same
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
KR101460999B1 (en) 2006-07-12 2014-11-17 유니버시티 오브 테네시 리서치 파운데이션 Substituted acylanilides and methods of use thereof
ITRM20060427A1 (en) 2006-08-04 2008-02-05 Nuraging Biotech S R L antioxidant compositions containing extracts of rosemary and myrtle
JP2008063328A (en) 2006-08-07 2008-03-21 Kowa Co Curative agent for glomerular disease
JP5507802B2 (en) 2006-08-10 2014-05-28 花王株式会社 Muscle aging inhibitors
US8703174B2 (en) 2006-09-15 2014-04-22 I Did It Inc Joint preserving nutritional vitamin, mineral and herbal pet supplement
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
CA2672420A1 (en) 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
MX2009007720A (en) 2007-01-16 2013-03-22 Ipintl Llc Novel composition for treating metabolic syndrome.
US20080319855A1 (en) 2007-02-16 2008-12-25 Stivoric John M Advertising and marketing based on lifeotypes
CN101657106B (en) 2007-02-23 2013-02-06 希尔氏宠物营养品公司 Compositions and methods for controlling the weight of animals
US20080233245A1 (en) 2007-03-19 2008-09-25 Lesley Joan White Liquid nutrient composition for improving performance
US20080242727A1 (en) 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
US20100210692A1 (en) 2007-03-28 2010-08-19 Farmer Stephen R Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
WO2008143182A1 (en) 2007-05-17 2008-11-27 Kaneka Corporation Composition containing licorice-derived polyphenol
US20100204204A1 (en) 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
US20090054450A1 (en) * 2007-06-19 2009-02-26 Ironwood Pharmaceuticals, Inc. Compositions and methods of use for treating or preventing lipid related disorders
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009003798A1 (en) 2007-07-05 2009-01-08 Unilever N.V. Food composition comprising trans-resveratrol and its use to control blood pressure
US20100130597A1 (en) 2007-07-06 2010-05-27 The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service Dna-pkcs modulates energy regulation and brain function
US8529965B2 (en) 2007-07-09 2013-09-10 Hill's Pet Nutrition, Inc. Compositions and methods for altering stool quality in an animal
WO2009033034A1 (en) 2007-09-07 2009-03-12 Nike, Inc. Wearable device assembly having athletic functionality
WO2009054994A2 (en) 2007-10-23 2009-04-30 President And Fellows Of Harvard College Use of compounds activating sirt-3 for mimicking exercise
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
CN105211641A (en) 2007-12-21 2016-01-06 希尔氏宠物营养品公司 Pet food composition
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
EA019309B1 (en) 2008-02-04 2014-02-28 Меркьюри Терапьютикс, Инк. Ampk (amp-activated protein kinase) modulators
JP5643116B2 (en) 2008-03-03 2014-12-17 ナイキ イノベイト セー. フェー. Interactive exercise equipment system
AU2009225721B2 (en) 2008-03-17 2014-02-13 The Procter & Gamble Company. User-customizable dosing system
JP5645809B2 (en) 2008-04-02 2014-12-24 ナイキ イノベイト セー. フェー. Wearable device assembly having a movement for the function
CN102088978B (en) 2008-07-07 2013-12-18 持田制药株式会社 Ameliorating or therapeutic agent for dyslipidemia
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
WO2010019212A2 (en) 2008-08-15 2010-02-18 Nestec S.A. Methods for enhancing energy metabolism
AU2009322474A1 (en) 2008-12-01 2011-07-21 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
CA2929927C (en) 2009-04-26 2018-09-11 Nike Innovate C.V. Gps features and functionality in an athletic watch system
US20100303966A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
US20100303967A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food Having Improved Animal Preference
EP2448413A4 (en) 2009-07-01 2013-02-13 Magceutics Inc Slow release magnesium composition and uses thereof
AU2010276259B2 (en) 2009-07-21 2013-04-18 Hill's Pet Nutrition, Inc. Companion animal nutrition system
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110064712A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
AU2010295412A1 (en) 2009-09-18 2012-05-03 Polifenoles Naturales, S.L. Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid
WO2011051974A1 (en) 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
US8173181B2 (en) 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
CA2785641C (en) 2009-12-29 2014-11-25 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
CA2785997A1 (en) 2010-01-06 2011-07-14 Nestec S.A. Dietary regimens useful for mimicking caloric restriction
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
JP5865242B2 (en) 2010-04-28 2016-02-17 日本薬品株式会社 Eye strain therapeutic composition
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (en) 2010-09-20 2013-04-24 王强 Special sea dietary food for diabetics
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
AU2012204162B2 (en) * 2011-01-07 2017-04-20 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
WO2012097064A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
JP6158801B2 (en) 2011-07-15 2017-07-05 ニューサート サイエンシーズ, インコーポレイテッド Compositions and methods for modulating the metabolic pathway
CA2845829A1 (en) 2011-08-19 2013-02-28 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR101409330B1 (en) 2012-05-11 2014-06-18 안국약품 주식회사 Sustained-Release combination preparations for the treatment of diabetes mellitus having enhanced compliance and preparation method thereof
CN108295058A (en) * 2012-11-13 2018-07-20 纽斯尔特科学公司 Compositions and methods for increasing energy metabolism
EP2945616B1 (en) 2013-01-15 2018-11-28 NuSirt Sciences, Inc. Treating pulmonary conditions
AU2014236687A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
AU2014238377A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
US20160213639A1 (en) 2013-10-07 2016-07-28 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
RU2016138136A3 (en) 2014-02-27 2018-09-26
WO2017040407A1 (en) 2015-09-01 2017-03-09 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)

Also Published As

Publication number Publication date
US20160067201A1 (en) 2016-03-10
CN106456997B (en) 2018-12-28
PH12016501668A1 (en) 2016-11-07
EP3110507A4 (en) 2017-11-01
JP2017506651A (en) 2017-03-09
US9724319B2 (en) 2017-08-08
AU2015222754A1 (en) 2016-09-08
CA2939833A1 (en) 2015-09-03
CN106456997A (en) 2017-02-22
ZA201605795B (en) 2018-05-30
US20170065545A1 (en) 2017-03-09
RU2016138136A (en) 2018-04-02
EP3110507A1 (en) 2017-01-04
KR20160119863A (en) 2016-10-14
IL247263D0 (en) 2016-09-29
US20180169043A1 (en) 2018-06-21
MX2016011063A (en) 2016-11-30
US9872844B2 (en) 2018-01-23
WO2015131152A1 (en) 2015-09-03
RU2016138136A3 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
GB201413025D0 (en) Beyond 3
SG11201610405RA (en) Compositions and methods for the expression of crispr guide rnas using the h1 promoter
EP3152319A4 (en) Methods and compositions for nuclease design
EP3142707A4 (en) Methods and compositions for prevention or treatment of a disease
IL248143D0 (en) Methods and compositions for immunomodulation
EP3119797A4 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
GB201801933D0 (en) Engineered crispr-CAS9 compositions and methods of use
TWI586701B (en) Copolycarbonate and composition comprising the same
EP3258925A4 (en) Methods and compositions for decreasing gastric emptying
GB201411197D0 (en) Composition and use thereof
EP3303634A4 (en) Cas9 variants and methods of use thereof
IL250744D0 (en) Method of producing palbociclib and pharmaceutical compositions comprising the same
EP3206497A4 (en) Compositions and methods for the treatment of meibomian gland dysfunction
SG11201605449YA (en) Compounds and compositions for immunotherapy
AP201709771A0 (en) Carrier-antibody compositions and methods of making and using the same
EP3102200A4 (en) Therapeutic compounds and compositions
IL252756D0 (en) Solid forms of an ask1 inhibitor
EP3325620A4 (en) Antiviral methods and compositions
IL259576D0 (en) Compositions and methods for immunooncology
HK1231471A1 (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2-
IL252216D0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL249362A (en) Pesticidal compositions and processes related thereto
EP3096757A4 (en) Apilimod compositions and methods for using same
EP3352584A4 (en) Compositions and methods for synthesizing 5'-capped rnas
IL248519D0 (en) Bioceramic compositions and biomodulatory uses thereof